Suven Life Sciences, Hyderabad-based Contract Research And Manufacturing Services (CRAMS) provider, received the US Food and Drug Administration (USFDA) acceptance for its Pashamylaram facility, near Hyderabad, to manufacture and supply active pharmaceutical ingredients and intermediates.
According to the company, the plant has undergone the US FDA renewal inspection for the manufacture and supply of active pharmaceutical ingredients (bulk drugs) and intermediates under cGMP. So far Suven Life Sciences has filed 16 Drug Master Files (DMF) and one Abbreviated New Drug Applications (ANDA) from this facility which is now FDA complaint under cGMP.